Figure 2. Combination therapies and multi-target KIs are able to overcome signalling re-activation and resistance.

This figure shows the effect of polytherapies on signalling in drug resistant cells. MRT cells develop resistance to PDGFR inhibitors (PDGFRi) by activating compensatory signalling pathways through upregulation of FGFR1. PDGFRi-resistant MRT cells are sensitive to polytherapies that target both FGFR1 and PDGFRA, either utilising a combination approach of PDGFRi and FGFR inhibitors (FGFRi) or a multi-target KI approach with a dual inhibitor.